Asia Pacific Immune Checkpoint Inhibitors Market Size & Outlook
Asia Pacific immune checkpoint inhibitors market, 2018-2030 (US$M)
Related Markets
Asia Pacific immune checkpoint inhibitors market highlights
- The Asia Pacific immune checkpoint inhibitors market generated a revenue of USD 5,387.9 million in 2023.
- The market is expected to grow at a CAGR of 21.8% from 2024 to 2030.
- In terms of segment, pd-1 was the largest revenue generating type in 2023.
- Other Types is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 5,387.9 million |
| Market revenue in 2030 | USD 21,472.2 million |
| Growth rate | 21.8% (CAGR from 2023 to 2030) |
| Largest segment | Pd-1 |
| Fastest growing segment | Other Types |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | PD-1, PD-L1, CTLA-4, Other Types |
| Key market players worldwide | Sanofi SA, Roche, Merck & Co Inc, Bristol-Myers Squibb Co, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Shanghai Junshi Biosciences Co Ltd Class H, BeiGene Ltd ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 11.1% of the global immune checkpoint inhibitors market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 21,472.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immune Checkpoint Inhibitors Market Scope
Immune Checkpoint Inhibitors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific immune checkpoint inhibitors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immune checkpoint inhibitors market will help companies and investors design strategic landscapes.
Pd-1 was the largest segment with a revenue share of 73.5% in 2023. Horizon Databook has segmented the Asia Pacific immune checkpoint inhibitors market based on pd-1, pd-l1, ctla-4, other types covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Immune Checkpoint Inhibitors Type Outlook (Revenue, USD Million, 2018-2030)
- PD-1
- PD-L1
- CTLA-4
- Other Types
- Asia Pacific Immune Checkpoint Inhibitors Application Outlook (Revenue, USD Million, 2018-2030)
- Lung Cancer
- Breast Cancer
- Bladder Cancer
- Melanoma
- Cervical Cancer
- Hodgkin Lymphoma
- Colorectal Cancer
- Other Applications
- Asia Pacific Immune Checkpoint Inhibitors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
Reasons to subscribe to Asia Pacific immune checkpoint inhibitors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific immune checkpoint inhibitors market databook
-
Our clientele includes a mix of immune checkpoint inhibitors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific immune checkpoint inhibitors market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific immune checkpoint inhibitors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific immune checkpoint inhibitors market
Asia Pacific Immune Checkpoint Inhibitors Market Share, 2023 & 2030 (US$M)
Asia Pacific immune checkpoint inhibitors market
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
